Program
Anti-CDH17 Antibody-drug Conjugate HS-20110
Also written as “Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin”, “Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin” and “Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine”.
In hoffmann la roche’s pipeline, CDH17 ADC
. Its studies are led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 22 open or running | phase 2since Dec 3, 2025 | Feb 24, 2025 | Dec 31, 2026phase 1 · NCT06892379 |
- Named in hoffmann la roche’s own pipeline as
RG6975 CDH17 ADC (Hansoh)
, phase 1, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Hoffmann-La Roche.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2025First study: phase 1 study in Solid TumorsFirst studyNCT06892379 · 475 planned · United States, China
- Dec 3, 2025Phase 2 study in CRCPhase 2 reachedNCT07283367 · 502 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Solid TumorsNCT06892379
- Dec 31, 2029Primary completion: phase 2 study in CRCNCT07283367
TargetBeta
“CDH17 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-17 (CDH17) ”NCIt, by rule
Other programs on CDH17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911rule | Mabwell (Shanghai) Bioscience | phase 2 | 2 |
| AMT-676rule | multitude-therapeutics-inc | phase 2 | 2 |
| Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324rule | dualitybio-inc | phase 2 | 1 |
| LM-350 | Sino Biopharmaceutical | phase 2 | 1 |
| Anti-CDH17 Antibody-drug Conjugate YL217rule | MediLink Therapeutics (Suzhou) | phase 1 | 1 |
| Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rule | arrivent-biopharma-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07283367CRC · China | 2 | Recruiting | Dec 31, 2029 | 502 |
| NCT06892379Solid Tumors · United States, China | 1 | Recruiting | Dec 31, 2026 | 475 |
How it is read
Names in the registry
- “Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin”, 1 entry
- “Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin”, 1 entry
- “Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine”, 1 entry
- “HS-20110 (Phase Ia:Dose escalation )”, 1 entry
- “HS-20110 (Phase Ib:Dose expansion )”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.